Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Tivicay (dolutegravir), Triumeq (dolutegravir, abacavir, lamivudine), Juluca (dolutegravir, rilpivirine) - Important Safety Information from Viiv Healthcare as approved by the HPRA
Notice type:
3rd Party Publications
Date:
25/05/2018
Problem Or Issue:
Important Safety Information communication from Viiv Healthcare: Tivicay (dolutegravir), Triumeq (dolutegravir, abacavir, lamivudine), Juluca (dolutegravir, rilpivirine) - Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception.
Important Safety Information - Tivicay (dolutegravir), Triumeq (dolutegravir, abacavir, lamivudine), Juluca (dolutegravir, rilpivirine)
« Back
Date Printed: 26/04/2024